# Cognitive Neurology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN-TD
- Date: 1984-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Mireille Haddad-Kowalski, MD, Cognitive Neurology
- Urgency: Routine; at the memory clinic two weeks from now, on the same day as his two-week primary care visit, with brain MRI and audiometry that morning

## Referral question

Two years of progressive memory loss with getting lost while driving in a retired professional boxer of 63 with type 2 diabetes and hypertension; MoCA 18. Please stage the impairment, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, advise on biomarker testing and on eligibility for anti-amyloid therapy, and help us plan safety and support. **S**

## Questions for the consultant

1. What is the stage of his impairment, and is the pattern most consistent with Alzheimer's disease?
2. How should we think about traumatic encephalopathy syndrome and chronic traumatic encephalopathy after his boxing career, and about vascular disease?
3. Which biomarker test do you advise, and should APOE genotyping be done?
4. Is he a candidate for lecanemab or donanemab under the appropriate use recommendations?
5. What do you advise for symptomatic treatment, driving, firearm safety, hearing and support for his care partner?

## Pertinent history

Retired world champion boxer: about 200 professional bouts over 25 years after an amateur career. Memory loss for about two years, worse in the past six months: repeated questions, missed bills and appointments, and lost twice in familiar streets while driving. Independent in personal care; needs help with finances and medicines (Functional Activities Questionnaire 11). MoCA 18 with losses in delayed recall, orientation and executive tasks; PHQ-9 4. About ten years of schooling. Diabetes on metformin and glipizide (hemoglobin A1c 6.4%); hypertension on lisinopril; atorvastatin. Diphenhydramine 25 mg nightly stopped today. Blood count, metabolic panel (creatinine 1.0 mg/dL, eGFR 85), B12 352 pg/mL and TSH 1.9 normal; urine albumin-to-creatinine ratio 14 mg/g. STOP-Bang 2. No anticoagulant. He has agreed not to drive until the work-up is done; a handgun at home is unloaded and locked with the key held by his care partner, who comes to visits. **S**

- He was born Walker Smith Jr. on May 3, 1921. The Michigan Sports Hall of Fame gives his birthplace as Ailey, Georgia, with the family later moving to Detroit; the 1989 UPI obituary says he was born in Detroit. **D**
- As a boy he moved with his family to Harlem in New York, and he won the Golden Gloves featherweight title in 1939. **D**
- He held the world welterweight championship, won in 1946, and the world middleweight title five times, first in 1951. **D**
- He boxed professionally from 1940 to 1965, about 200 bouts in all: the 1989 UPI obituary counts 201 fights, 109 won by knockout and 65 by decision; the 1987 UPI report gives a record of 174-19-6 and the Michigan Sports Hall of Fame 173-19-6. **D**
- After boxing he settled in Los Angeles, living modestly in the top story of a duplex on West Adams Boulevard, and in 1969 founded the Sugar Ray Robinson Youth Foundation for inner-city children in the Los Angeles area. **D**
- The project roster describes his dementia as probable boxing-related dementia pugilistica; no source read records that diagnosis, chronic traumatic encephalopathy, or an autopsy finding. **R**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: White blood cells: 6.4 10*3/uL; Hemoglobin: 14.1 g/dL; Platelets: 231 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1979): 85 mL/min/1.73 m²; Glucose: 126 mg/dL; Hemoglobin A1c: 6.4% (high); Vitamin B12: 352 pg/mL; TSH: 1.9 mIU/L; Urine albumin-to-creatinine ratio: 14 mg/g; MoCA: 18; PHQ-9: 4. All results are synthetic.

BP 132/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 77 kg; BMI 23.8 kg/m². All vital signs are synthetic.

## Current medications

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Glipizide 5 mg oral tablet, one tablet before breakfast **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Plan so far

- Dementia work-up under the Alzheimer's Association guideline: history from him and his care partner, MoCA, function, depression screening, first-tier blood tests (blood count, metabolic panel, B12, TSH), a review of medicines for anticholinergic and sedating drugs, a sleep apnea screen, and brain MRI. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026) **S**
- Stop diphenhydramine, a strongly anticholinergic sleep aid; sleep habits and morning light instead. Guideline: American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023) **S**
- Driving: no driving until the evaluation is complete, with his care partner driving; firearm: unloaded and locked, with the key held by his care partner, until a decision with him. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Practice Parameter update: Evaluation and management of driving risk in dementia (2010) **S**
- Blood pressure under 130/80 mmHg on lisinopril, with potassium and creatinine checks. Guideline: CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
- Advance care planning while he can take part fully: a health care agent and his values, at the preventive visit. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024) **S**
- Exercise, social activity and diabetes and blood pressure control as the brain-health measures with the most support. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
